Role of apoptosis in congenital hematologic disorders and bone marrow failure

Reviews in Clinical and Experimental Hematology

Volumn 7, Issue 1, 2003, Pages 57-71

  Debatin, Klaus Michael ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOPOIETIC GROWTH FACTOR;

APLASTIC ANEMIA; APOPTOSIS; BONE MARROW DEPRESSION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC DISEASE; HEMATOLOGIC DISEASE; HEMATOPOIESIS; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; HOMEOSTASIS; LEUKEMIA; LYMPHOCYTE PROLIFERATION; NEUTROPENIA; PATHOPHYSIOLOGY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STEM CELL;

APOPTOSIS; BONE MARROW DISEASES; HEMATOLOGIC DISEASES; HEMATOPOIESIS; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; SIGNAL TRANSDUCTION;

EID: 0141857390     PISSN: 11270020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Wickremasinghe RG and Hoffbrand AV. Biochemical and genetic control of apoptosis: relevance to normal hematopoiesis and hematological malignancies. Blood, 93: 3587-3600, 1999.
2. Schimmer AD, Hedley DW, Penn LZ et al. Receptor and mitochondrial-mediated apoptosis in acute leukemia: a translational view. Blood, 98: 3541-3553, 2001.
3. Lotem J and Sachs L. Cytokine control of developmental programs in normal hematopoiesis and leukemia. Oncogene, 21: 3284-3294, 2002.
4. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell, 108: 153-164, 2002.
5. Herr I and Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood, 98: 2603-2614, 2001.
6. Evan GI and Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature, 411: 342-348, 2001.
7. El-Deiry WS. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr Opin Oncol, 9: 79-87, 1997.
8. Igney FH and Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer, 2: 277-288, 2002.
9. Debatin KM. Cytotoxic Drugs, Progmmmed Cell Death, and the Immune System: Defining New Roles in an Old Play. J Natl Cancer Inst. 89: 750-751, 1997.
10. Surh CD and Sprent J. T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature, 372: 100-103, 1994.
11. Siegel RM, Chan FK, Chun HJ, et al. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nature Immunol, 1: 469-474, 2000.
12. Williams GT, Smith CA, Spooner E, et al. Haematopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature, 343: 76, 1990.
13. Los M, Wesselborg S, Schulze-Osthoff K. The role of caspases in development, immunity, and apoptotic signal transduction: lessons from knockout mice. Immunity 10: 629-639, 1999.
14. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem, 68: 383-424, 1999.
15. Krammer PH. CD95's deadly mission in the immune system. Nature, 407: 789-795, 2000.
16. Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J, 17: 1675-1687, 1998.
17. Kroemer G and Reed JC. Mitochondrial control of cell death. Nature Med, 6: 513-519, 2000.
18. Roy S and Nicholson DW. Cross-talk in cell death signaling. J Exp Med, 192: 21-26, 2000.
19. Slee EA, Adrian C, Martin SJ. Serial killers: ordering caspase activation events in apoptosis. Cell Death Differ, 6: 1067-1074, 1999.
20. Walczak H and Krammer PH. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res, 256: 58-66, 2000.
21. Du C, Fang M, Li Y, et al. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell, 102: 33-42, 2000.
22. Nagata S. Apoptotic DNA fragmentation. Exp Cell Res, 256: 12-18, 2000.
23. Cory S and Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer, 2: 647-56, 2002.
24. Bouilett P, Purton JF, Godfrey DI, et al. BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature, 415: 922-926, 2002.
25. O'Reilly LA, Cullen L, Visvader J, et al. The proapoptotic BH3-only protein bim is expressed in hematopoietic, epithelial, neuronal, and germ cells. Am J Pathol, 157: 449-461, 2000.
26. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol, 3: 401-410, 2002.
27. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature, 408: 307-310, 2000.
28. Lassus P, Opitz-Araya X, Lazebnik Y. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science, 297: 1352-1354, 2002.
29. Cowburn AS, Cadwallader KA, Reed BJ, et al. Role of PI3-kinase-dependent Bad phosphorylation and altered transcription of cytokine-mediated neutrophil survival. Blood, 100: 2607-2616, 2002.
30. Cohen PL and Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol, 9: 243-269, 1991.
31. Watanabe-Fukunaga R, Brannan CI, Copeland NG, et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature, 356: 314-317, 1992.
32. Takahashi T, Tanaka M, Brannan CI, et al. Generalized lymphoproliferative disease in mice, caused bv a point mutation in the Fas ligand. Cell, 76: 969-976, 1994.
33. Adachi M, Suematsu S, Suda T, et al. Enhanced and accelerated lymphoproliferation in Fas-null mice. Proc Natl Acad Sci USA, 93: 2131-2136, 1996.
34. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature, 335: 440-442, 1988.
35. Veis DJ, Sorenson CM, Shutter JR, et al. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell, 75: 229-240, 1993.
36. Motoyama N, Wang F, Roth KA, et al. Massive cell death of immature hematopoietic cells and neurons in bcl-x-deficient mice. Science, 267: 1506-1510, 1995.
37. Yeh WC, Pompa JL, McCurrach ME, et al. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science, 279: 1954-1958, 1998.
38. Newton K, Harris AW, Bath ML, et al. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J, 17: 709-718, 1998.
39. Lens SMA, Kataoka T, Fortner KA, et al. The Caspase 8 Inhibitor c-FLIPL Modulates T-Cell Receptor-Induced Proliferation but Not Activation-Induced Cell Death of Lymphocytes. Mol Cell Biol, 22: 5419-5433, 2002.
40. Barcena A, Park SW, Banapour B, et al. Expression of Fas/CD95 and Bcl-2 by primitive hematopoietic progenitors freshly isolated from human fetal liver. Blood, 88: 2013-2025, 1996.
41. Iwai K, Miyawaki T, Takizawa T, et al. Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes and neutrophils. Blood, 84: 1201-1208, 1994.
42. Park JR, Bernstein ID, Hockenbery DM. Primitive human hematopoietic precursors express bcl-x but not bcl-2. Blood, 86: 868-876, 1995.
43. Philpott NJ, Prue RL, Marsh JC, et al. G-CSF-mobilized CD34 peripheral blood stem cells are significantly less apoptotic than unstimulated peripheral blood CD34 cells: role of G-CSF as survival factor. Br J Haematol, 97: 146-152, 1997.
44. Akbar AN, Borthwick NJ, Wickremasinghe RG, et al. Interleukin-2 receptor common gamma-chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: selective induction of anti-apoptotic (bcl-2, bcl-xL) but not proapoptotic (bax, bcl-xS) gene expression. Eur J Immunol, 26: 294-299, 1996.
45. Ritchie A, Gotoh A, Gaddy J, et al. Thrombopoietin upregulates the promoter conformation of p53 in a proliferation-independent manner coincident with a decreased expression of Bax: potential mechanisms for survival enhancing effects. Blood, 90: 4394-4402, 1997.
46. Weber Nordt RM, Henschler R, Schott E, et al. Interleukin-10 increases Bcl-2 expression and survival in primary human CD34+ hematopoietic progenitor cells. Blood, 88: 2549-2558, 1996.
47. McDonnell TJ, Deane N, Platt FM, et al. Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell, 57: 79-88, 1989.
48. Strasser A, Harris AW, Bath ML, et al. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature, 348: 331-333, 1990.
49. Blandino G, Scardigli R, Rizzo MG, et al. Wild-type p53 modulates apoptosis of normal, IL-3 deprived, hematopoietic cells. Oncogene, 10: 731-737, 1995.
50. Dhein J, Walczak H, Baeumler C, et al. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature, 373: 438, 1995.
51. Stahnke K, Hecker S, Kohne E, et al. CD95 (APO-1/FAS) mediated apoptosis in cytokine-activated hematopoietic cells. Exp-Hematol, 26: 844-850, 1998.
52. Liles WC, Kiener PA, Ledbetter JA, et al. Differential expression of Fas (CD 95) and Fas-ligand on normal human phagocytes: implications for regulation of apoptosis in neutrophils. J Exp Med, 184: 429-440, 1996.
53. Fischer A, Rieux-Laucat F, Le-Deist F. A new peak in the ALPS. Nature Med, 5: 876-877, 1999.
54. Fisher GH, Rosenberg FJ, Straus SE, et al. Dominant Interfering Fas Gene Mutations Impair Apoptosis in a Human Autoimmune Lymphoproliferative Syndrome. Cell, 81: 935-946, 1995.
55. Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in Fas Associated with Human Lymphoproliferative Syndrome and Autoimmunity. Science, 268: 1347-1349, 1995.
56. Drappa J, Vaishnaw AK, Sullivan KE, et al. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med, 335: 1643-1649, 1996.
57. Behrmann I, Walczak H, Krammer PH. Structure of the human APO-1 gene. J Immunol, 24: 3057-3062, 1994.
58. Fiucci G and Ruberti G. Detection of polymorphisms within the FAS cDNA gene sequence by GC-clamp denaturing gradient gel electrophoresis. Immunogenetics, 39: 437-439, 1994.
59. Siegel RM, Frederiksen JK, Zacharias DA, et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science, 288: 2354-2357, 2000.
60. Martin DA, Zheng L, Siegel RM, et al. Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia. Proc Natl Acad Sci USA, 96: 4552-4557, 1999.
61. Itzui S, Kelley VE, Masuda K, et al. Induction of various autoantibodies by mutant gene lpr in several strains of mice. J Immunol, 133: 227-233, 1984.
62. Wang J, Zheng L, Lobito A, et al. Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell, 98: 47-58, 1999.
63. Ramenghi U, Bonissoni S, Migliaretti G, et al. Deficiency of the Fas apoptosis pathway without Fas gene mutations is a familial trait predisposing to development of autoimmune diseases and cancer. Blood, 95: 3176-3182, 2000.
64. Straus SE, Jaffe ES, Puck JM, et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood, 98: 194-200, 2001.
65. Beltinger CP, Kurz E, Böhler T, et al. CD95(APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia. Blood, 91: 3943-3951, 1998.
66. Beltinger CP, Böhler T, Karawajew L, et al. Mutation analysis of CD95 (APO-1/Fas) in childhood B-lineage acute lymphoblastic leukaemia. Br J Haematol, 102: 722-728, 1998.
67. Landowski LH, Qu N, Buyuksal I, et al. Mutations in the Fas antigen in patients with multiple myeloma. Blood, 90: 4266-4270, 1997.
68. Tamiya S, Etoh K, Suzushima H, et al. Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells. Blood, 91: 3935-3942, 1998.
69. Muschen M, Re D, Brauninger A, et al. Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells. Cancer Res, 60: 5640-5643, 2000.
70. Gronbaek K, Straten PT, Ralfkiaer E, et al. Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood, 92: 3018-3024, 1998.
71. Muschen M, Warskulat U, Beckmann MW. Defining CD95 as a tumor suppressor gene. J Mol Med, 78: 312-325, 2000.
72. Schirmer M, Vallejo AN, Weyand CM, et al. Resistance to apoptosis and elevated expression of Bcl-2 in clonally expanded CD4+CD28- T cells from rheumatoid arthritis patients. J Immunol, 161: 1018-1025, 1998.
73. Liu JH, Wei S, Lamy T, et al. Chronic neutropenia mediated by Fas ligand. Blood, 95: 3219-3222, 2000.
74. Aprikyan AAG, Liles WC, Rodger E, et al. Impaired survival of bone marrow hematopoietic progenitor cells in cyclic neutropenia. Blood, 97: 147-153, 2001.
75. Irvine AE, Magill MK, Somerville LE, et al. Spontaneous intramedullary apoptosis is present in disorders other than myelodysplasia. Exp Hematol, 26: 435-439, 1998.
76. Dale DC, Person RE, Bolyard AA, et al. Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood, 96: 2317-2322, 2000.
77. Li FQ and Horwitz M. Characterization of Mutant Neutrophil Elastase in Severe Congenital Neutropenia. J Biol Chem, 276: 14230-14241, 2001.
78. Grenda DS, Johnson SE, Mayer IR, et al. Mice expressing a neutrophil elastase mutation derived from patients with severe congenital neutropenia have normal granulopoiesis. Blood, 100: 3221-3228, 2002.
79. Aprikyan AAG, Liles WC, Park JR, et al. Myelokathexis, a congenital disorder of severe neutropenia characterized by accelerated apoptosis and defective expression of bcl-x in neutrophil precursors. Blood, 95: 320-327, 2001.
80. Dror Y and Freedman MH. Shwachman-Diamond syndrome marrow cells show abnormally increased apoptosis mediated through the Fas pathway. Blood, 97: 3010-3016, 2001.
81. Mack DR, Forstner GG, Wilschanik M, et al. Shwachman syndrome: exocrine pancreatic dysfunction and variable phenotypic expression. Gastroenterology, 111: 1593-1602, 1996.
82. Dror Y, Durie P, Ginzberg H, et al. Clonal evolution in marrows of patients with Shwachman-Diamnond syndrome: A prospective 5-year follow-up study. Exp Hematol, 30: 659-669, 2002.
83. Ridet A, Guillouf C, Duchaud E, et al. Deregulated apoptosis is a hallmark of the Fanconi anemia syndrome. Cancer Res, 57: 1722-1730, 1997.
84. Centis F, Tabellini L, Lucarelli G, et al. The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with β-thalassemia major. Blood, 96: 3624-3629, 2000.
85. Wang J, Otsuki T, Youssoufian H, et al. Overexpression of the Fanconi anemia group C gene (FAC) protects hematopoietic progenitors from death induced by Fas-mediated apoptosis. Cancer Res, 58: 3538-3541, 1998.
86. Rathbun RK, Faulkner GR, Ostroski MH, et al. Inactivation of the Fanconi anemia group C gene augments interferon-γ-induced apoptotic responses in hematopoietic cells. Blood, 90: 974-985, 1997.
87. Perdahl EB, Naprstek BL, Wallace WC, et al. Erythroid failure in Diamond-Blackfan anemia is characterized by apoptosis. Blood, 83: 645-650, 1994.
88. Ismail M, Gibson FM, Gordon-Smith EC, et al. Bcl-2 and Bcl-x expression in the CD34+ cells of aplastic anemia patients; relationship with increased apoptosis and upregulation of Fas antigen. Br J Haematol, 113: 706-712, 2001.
89. Vibhuti T, Naresh K, Nityanand S. Massive apoptosis of bone marrow cells in aplastic anaemia. Br J Haematol, 117: 993-994, 2002.
90. Ismail M, Gibson FM, Gordon-Smith EC, et al. Bcl-2 and Bcl-x expression in the CD 34+ cells of aplastic anaemia patients: relationship with increased apoptosis and upregulation of Fas antigen. Br J Haematol, 113: 706-712, 2001.
91. Maciejewski JC, Selleri T, Sato S, et al. Increased expression of Fas antigen on bone marrow of patients with aplastic anaemia. Br J Haematol, 91: 245-252, 1995.
92. Luther-Wyrsch A, Nissen C, Wodnar-Filipowicz A. Intracellular Fas ligand is elevated in T lymphocytes in severe aplastic anaemia. Br J Haematol, 114: 884-890, 2001.
93. Maciejewski JC, Selleri S, Anderson NS, et al. Fas antigen expression on CD34+ human bone marrow cells is induced by interferon γ and tumor necrosis factor α and potentiates cytokine-mediated hematopoietic supression in vitro. Blood, 85: 3183-3190, 1995.
94. Shetty V, Hussaini S, Broady-Robinson L, et al. Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: apoptotic cells recovered from high-density fraction of bone marrow aspirates. Blood, 96: 1388-1392, 2000.
95. Bouscary D, Chen YL, Guesnu M, et al. Activity of the caspase-3/CPP32 enzyme is increased in "early stage" myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro. Exp Hematol, 28: 784-791, 2000.
96. Parker JE, Mufti GJ, Rasool F, et al. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood, 96: 3932-3938, 2000.
97. Bogdanovic AD, Jankovic GM, Colovic MD, et al. Apoptosis in bone marrow of myelodysplastic syndrome patients. Blood, 87: 3064, 1996.
98. Rajapaksa R, Ginzton N, Rott LS, et al. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood, 88: 4275-4287, 1996.
99. Gersuk GM, Beckham C, Loken MR, et al. A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol, 103: 176-188, 1998.
100. Gupta P, Niehans GA, LeRoy SC, et al. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival. Leukemia, 13: 44-53, 1999.
101. Claessens YE, Bouscary D, Dupont JM, et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood, 99: 1594-1601, 2002.
102. Bäumler CB, Böhler T, Herr I, et al. Activation of the CD95 (APO-1/Fas) System in T Cells From Human Immunodeficiency Virus Type-1-Infected Children. Blood, 88: 1741-1746, 1996.
103. Gougeon ML, Debatin KM. Molecular control of programmed cell death in human immunodeficiency virus infection. Contribution to the dysregulation of T cell homeostasis and to CD4 T cell depletion. In: HIV and the New Viruses, R. Weiss and A. Dalgleish Eds., Academic Press, London, pp 99-114, 1999.
104. Zamai L, Secchiero P, Pierpaoli S, et al. TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. Blood, 95: 3716-3724, 2000.
105. Zang DY, Goodwin RG, Loken MR, et al. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood, 98: 3058-3065, 2001.